Among firms presenting on the first day, Roche provided insights into its COVID-19 testing business, and Guardant said it plans to launch a comprehensive tissue sequencing assay.
The liquid biopsy's firm's net loss rose significantly year over year, but it beat the top line consensus Wall Street estimate, with total revenues of $74.6 million for the quarter.
Though Guardant and Foundation have pioneered a path through the FDA for liquid biopsy tests, label differences highlight complex choices for oncologists.
Streck said its collection tube maintains native cell-free DNA populations and provides sample integrity by reducing the release of cellular genomic DNA.
The company was able to ramp up recruitment for its pivotal ECLIPSE trial after hurdles caused a falloff during the earlier months of the COVID-19 pandemic.
The assay provides comprehensive genomic information to oncologists from a blood draw, using targeted next-generation sequencing of circulating cell-free DNA.
